- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
PEG-Loxe improves weight loss and glycemic control in super-obese T2DM patients
Last updated July 18, 2026
Key finding
Weight reduction of -16.34 kg (95% CI: -19.10, -13.58) compared to placebo.
Polyethylene glycol loxenatide (PEG-Loxe) for weight reduction and metabolic improvement in super-obese patients with type 2 diabetes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Polyethylene glycol loxenatide (PEG-Loxe) for weight reduction and metabolic improvement in super-obese patients with type 2 diabetes.
Clinical relevance
This study evaluated Polyethylene glycol loxenatide (PEG-Loxe) for weight reduction and metabolic improvement in super-obese patients with type 2 diabetes.
Keep in mind
Limitations were not clearly described in the extracted text.
Published in
Journal Reference
Publication details and source links for this paper.
Zenglin L, Changrong S, Yunlu C, Zhewen L, Sanyuan H. Efficacy and Safety of Polyethylene Glycol Loxenatide for Weight Reduction and Metabolic Improvement in Super-Obese Patients with Type 2 Diabetes Mellitus. Frontiers in Endocrinology. 2026;17:1689040. doi:10.3389/fendo.2026.1689040
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to PEG-Loxe 300 µg/week, PEG-Loxe 400 µg/week and Body weight, HDL cholesterol, HbA1c, and 1 more.
This study contributes evidence to
Primary intervention
PEG-Loxe 300 µg/week
Primary outcomes
- Body weight
- HDL cholesterol
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
8
Evidence pairs
462
Related studies
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
Weight Loss
matched_outcome
Related evidence
Evidence topic
HbA1c Reduction
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Waist circumference
PEG-Loxe 300 µg/week → Waist circumference
PEG-Loxe 300 µg/week → Waist circumference
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Waist circumference
PEG-Loxe 400 µg/week → Waist circumference
PEG-Loxe 400 µg/week → Waist circumference
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on PEG-Loxe 300 µg/week and Body Weight, PEG-Loxe 300 µg/week and HbA1c.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
PEG-Loxe 300 µg/week → Body Weight
Medications
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
PEG-Loxe 300 µg/week → HbA1c
Medications
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Adipokine and Angiogenic Markers Evidence Hub
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
Measures Body Weight as a key outcome.
HbA1c Evidence Hub
All studies measuring HbA1c
Measures HbA1c as a key outcome.
PEG-Loxe 300 µg/week Evidence Hub
All studies on PEG-Loxe 300 µg/week
Contributes to PEG-Loxe 300 µg/week evidence base.
Recent Diabetes Research
Latest published studies
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on PEG-Loxe 300 µg/week and Body weight
1 results
All studies on PEG-Loxe 300 µg/week and HbA1c
1 results
All studies on PEG-Loxe 300 µg/week
1 results
All studies measuring Body weight
1 results
All studies measuring HbA1c
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does PEG-Loxe 300 µg/week affect body weight?
PEG-Loxe 300 µg/week appears to improve Body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does PEG-Loxe 400 µg/week affect body weight?
PEG-Loxe 400 µg/week appears to improve Body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does PEG-Loxe 300 µg/week improve hdl cholesterol?
Current evidence does not show a clear benefit of PEG-Loxe 300 µg/week for HDL cholesterol.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does PEG-Loxe 300 µg/week improve HbA1c?
Current evidence does not show a clear benefit of PEG-Loxe 300 µg/week for HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.
